Sep 2026· Human Cell· Vol 39· 0 citations· 27 references
Medicine
TL;DR
HNRNPC contributes malignant progression of ccRCC, at least in part, by recognizing m6A modifications on AURKB mRNA and enhancing its stability, suggesting that the HNRNPC/AURKB axis may serve as a potential therapeutic target for ccRCC.
Thyroid cancer (THCA) is the most common endocrine malignancy worldwide, understanding the pathophysiological mechanism is vital for developing effective strategies for prevention, diagnosis, and treatment. In this study, paired tumor and adjacent noncancerous tissues were collected from THCA patients. Cell viability a...
Lin Guo, Senhe Jiang, Xuehan Wang et al.· Molecular Carcinogenesis· 0 citations
An ERα/HNRNPC/DDX6 axis in ER+ breast cancer is unveiled, wherein ERα transcriptionally upregulates HNRNPC, which in turn stabilizes DDX6 mRNA in an m6A-dependent manner to drive tumor progression, suggesting HNRNPC as a promising therapeutic target.
Zi-Wei Huang, Wen-Jie Xu, Yun-Xiao Xiao et al.· British Journal of Cancer· 0 citations
Clinically, these findings identify the METTL1/USP48/LCN2 pathway as a potential therapeutic target for cSCC and elucidated a novel oncogenic axis in cSCC, wherein METTL1 stabilized USP48 mRNA through m7G methylation modification, and USP48 in turn deubiquitinated and stabilized LCN2 protein.
Xiu-Qi Li, Lin Shu, Xiao-Qiang Li et al.· Applied Biochemistry and Bio...· 0 citations
These findings identify La/SSB as a clinically relevant factor associated with HNSCC progression and CDDP responsiveness, and support a TFAP2C/FSCN1-linked regulatory framework that may contribute to malignant phenotypes.
This study aimed to clarify the functional regulatory links among RPA3, GPR87 and p53 in the tumorigenesis and progression of non-small cell lung cancer (NSCLC). Bioinformatic analysis and Western blot assays were performed to evaluate the expression profiles of RPA3 and GPR87 in NSCLC. CCK-8, EdU, wound healing, Trans...
Yang Yu, Wenwen Gao, Wenjuan Liu et al.· Gene· 0 citations
INTRODUCTION
Hepatocellular carcinoma (HCC) accounts for 75-85% of primary liver cancer cases and remains a major cause of cancer-related mortality worldwide. Despite its high incidence, there is currently no definitive cure for most patients, and the underlying molecular mechanisms are not fully understood.
METHODS...
Wei-Wei Wang, Sen Lu, Feng Jiao et al.· Anti-Cancer Agents in Medici...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.